Comment on: Benchmarking tocilizumab use for giant cell arteritis

Janagan, Shalini; Guly, Catherine; Skeoch, Sarah; Robson, Joanna C

Abstract

It is with great interest we read the editorial on tocilizumab (TCZ) use in giant cell arteritis (GCA) published on 9th May, 2022 by Conway et al [1]. We write to share some of our data to add weight to the views expressed, particularly in relation to use of TCZ beyond one year
in refractory cases with visual involvement.

Citation

Janagan, S., Guly, C., Skeoch, S., & Robson, J. C. (2022). Comment on: Benchmarking tocilizumab use for giant cell arteritis. Rheumatology Advances in Practice, 6(3), Article rkac069. https://doi.org/10.1093/rap/rkac069

• Journal Article Type: Article
• Acceptance Date: Aug 12, 2022
• Online Publication Date: Aug 23, 2022
• Publication Date: Sep 16, 2022
• Deposit Date: Sep 30, 2022
• Publicly Available Date: Sep 30, 2022
• Journal: Rheumatology Advances in Practice
• Print ISSN: 2514-1775
• Electronic ISSN: 2514-1775
• Publisher: Oxford University Press
• Peer Reviewed: Not Peer Reviewed
• Volume: 6
• Issue: 3
• Article Number: rkac069
• DOI: https://doi.org/10.1093/rap/rkac069
• Keywords: Rheumatology, tocilizumab, giant cell arteritis, arteritis
• Public URL: https://uwe-repository.worktribe.com/output/9943949
• Publisher URL: https://academic.oup.com/rheumap/article/6/3/rkac069/6673922?login=true
• Related Public URLs: Companion paper: Benchmarking tocilizumab use for giant cell arteritis, Conway et al, Rheumatology Advances in Practice, Volume 6, Issue 2, 2022, rkac037, https://doi.org/10.1093/rap/rkac037